Descripción de la oferta
New ImMunotherapy strategies against OVarian Cancer (IMCOV) research project is a translational project to be developed at IDIS in collaboration with CIBERONC and SunRock Biopharma. Ovarian cancer is the 7th most common cancer in women and the most lethal gynecological malignancy worldwide, making necessary the search of new therapeutic approaches. The purpose of IMCOV is to develop a new immunotherapeutic strategy for ovarian cancer based on first-in-class antibodies against chemokine receptor CCR9.
We offer a postdoctoral contract until end of 2024 (33.000 euros/year approx. gross salary).
The candidate will design and develop the experiments of IMCOV research project in a dynamic, international, and translational research group.
Perfil buscado
We are looking for highly motivated and enthusiastic individuals who are interested in this topic. Candidates must hold a PhD in Biology, Biochemistry, Biotechnology, Chemistry, Pharmacy, Medicine, or related topic.
Experience in cell culture and molecular biology is required.
We will positively evaluate any of the following experience and duties:
− Tumoral models and preclinical research.
− Immunotherapy techniques (monoclonal antibodies, adoptive cell therapies, etc).
− Laboratory animal training accreditations for carrying out procedures.
− Scientific articles in indexed journals (oncology and biomedical research fields).
− Stays in international biomedical research centers.
− English skills.
Presentación de solicitudes
If interested, please send us a copy of your CV, a motivation letter (1 page max.) and contact information of references to anxo.vidal@usc.es.
Applications will be considered until position is filled.